Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease.
Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 8, 2022 | Series A | $15.10M | 6 |
Hatteras Venture Partners
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
Hatteras Venture Partners
|
Yes | Series A |
Laerdal Million Lives Fund
|
— | Series A |
|
|
— | Series A |
Portal Innovations
|
— | Series A |
UnityPoint Health Ventures
|
— | Series A |